Greenwich LifeSciences, Inc.

12.63 USD
-0.37 (-2.85%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Greenwich LifeSciences, Inc. stock is up 44.51% since 30 days ago. The next earnings date is Apr 1, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 75% of the previous 3 March’s closed higher than February. 100% of analysts rate it a buy.

About Greenwich LifeSciences, Inc.

Greenwich LifeSciences focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.